Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Nancy Lin, MD
Study ID
NCT03417544
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Central Nervous System Metastases
  • HER2-positive Metastatic Breast Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ATEZOLIZUMAB — DRUG
    (IV) every 3 weeks
  • PERTUZUMAB — DRUG
    Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
  • TRASTUZUMAB — DRUG
    Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks

Study Details

This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab

Key Dates

Start date
May 21, 2018
Status verified
Apr 2026
Primary completion
May 20, 2020
Completion
May 31, 2026

Study Design

Enrollment
19 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
    Patients will receive the following treatment: * Atezolizumab (IV) every 3 weeks (q3w)\] * Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV) * High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w).

Primary Outcome Measure

Confirmed Overall Response Rate in CNS [ Time Frame: Participants were evaluated for response every 6 weeks for the first 24 weeks and then every 9 weeks thereafter, through study completion, an average of 24 weeks in the real study data ]

Locations (2)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611-
Dana-Farber Cancer InstituteBostonMassachusetts02215-

Find similar trials in Chicago, IL

By research site
Northwestern University· Chicago, ILDana-Farber Cancer Institute· Boston, MA

Related Studies